Related Experiment Video
Updated: Jul 20, 2026
11:35
The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
Published on: June 30, 2014
[Interferon-beta response in multiple sclerosis associated with pre-treatment disability].
O Fernandez-Fernandez1, V E Fernandez-Sanchez, C Mayorga
1Instituto de Neurociencias Clínicas, Hospital Regional Universitario Carlos Haya, Málaga, Espana.
Revista De Neurologia
|September 19, 2006
Summary
Pre-treatment disability impacts response to interferon-beta (IFNB) in multiple sclerosis. Neutralizing antibodies (NABs) to IFNB may delay relapses, suggesting careful patient selection is crucial.
Area of Science:
- Neuroimmunology
- Pharmacology
Context:
- Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
- Interferon-beta (IFNB) is a common disease-modifying therapy for MS.
- Neutralizing antibodies (NABs) can develop against IFNB, potentially impacting treatment efficacy.
Purpose:
- To investigate the association between pre-treatment clinical features and patient response to IFNB therapy in multiple sclerosis.
- To evaluate the influence of NABs to IFNB on the clinical outcomes of MS patients.
Summary:
- This study analyzed 96 multiple sclerosis patients treated with IFNB, assessing clinical characteristics and NABs.
- Higher baseline Expanded Disability Status Scale (EDSS) scores were observed in non-responders.
- NAB-negative patients experienced longer time-to-first-relapse and higher relapse-free rates, though association with disability status was not significant due to sample size.
Impact:
- Pre-treatment disability, measured by EDSS, is a significant predictor of IFNB treatment response in MS.
- The presence of NABs to IFNB appears to have a delayed negative impact on relapse rates.
- Findings suggest that baseline disability and antibody development are critical factors in IFNB therapy effectiveness for MS.
More Related Videos
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...